Navidea Biopharmaceuticals, Inc. NAVB, a biopharmaceutical company
focused on precision diagnostic radiopharmaceuticals, today announced it has
entered into an agreement to collaborate with Maimonides Medical Center to
investigate the utility of Lymphoseek (technetium Tc 99m tilmanocept)
Injection in lymphatic mapping procedures for colorectal cancer. Dr. Danny
Sherwinter, surgeon and the Director of the Department of Minimally Invasive &
Bariatric Surgery at Maimonides Medical Center in Brooklyn, NY, will lead the
investigator-initiated clinical study. This open-label evaluation, expected to
start enrollment in early 2013, will be performed at Maimondes and will
include the assessment of lymph nodes from up to 40 colon cancer subjects.
According to the American Cancer Society, approximately 140,000 new cases of
colorectal cancer are expected to be diagnosed in the United States annually^1
while worldwide annual diagnosis is over 1.2 million.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in